- Home
- CVKD vs DYAI Comparison
CVKD vs DYAI Comparison
Compare CVKD & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- DYAI
- Stock Information
- Founded
- CVKD 2022
- DYAI 1979
- Country
- CVKD United States
- DYAI United States
- Employees
- CVKD N/A
- DYAI N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVKD Health Care
- DYAI Health Care
- Exchange
- CVKD Nasdaq
- DYAI Nasdaq
- Market Cap
- CVKD 29.5M
- DYAI 30.2M
- IPO Year
- CVKD 2023
- DYAI 2004
- Fundamental
- Price
- CVKD $11.15
- DYAI $0.94
- Analyst Decision
- CVKD Strong Buy
- DYAI Strong Buy
- Analyst Count
- CVKD 1
- DYAI 1
- Target Price
- CVKD $32.00
- DYAI $6.00
- AVG Volume (30 Days)
- CVKD 27.6K
- DYAI 213.1K
- Earning Date
- CVKD 08-19-2025
- DYAI 08-13-2025
- Dividend Yield
- CVKD N/A
- DYAI N/A
- EPS Growth
- CVKD N/A
- DYAI N/A
- EPS
- CVKD N/A
- DYAI N/A
- Revenue
- CVKD N/A
- DYAI $3,554,344.00
- Revenue This Year
- CVKD N/A
- DYAI $22.56
- Revenue Next Year
- CVKD N/A
- DYAI $30.95
- P/E Ratio
- CVKD N/A
- DYAI N/A
- Revenue Growth
- CVKD N/A
- DYAI 57.59
- 52 Week Low
- CVKD $5.70
- DYAI $0.91
- 52 Week High
- CVKD $22.90
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- CVKD 48.44
- DYAI 40.23
- Support Level
- CVKD $10.14
- DYAI $0.97
- Resistance Level
- CVKD $11.44
- DYAI $1.04
- Average True Range (ATR)
- CVKD 0.75
- DYAI 0.09
- MACD
- CVKD 0.07
- DYAI -0.02
- Stochastic Oscillator
- CVKD 74.38
- DYAI 6.92
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.